Document:

Amendment No. 1 to Manufacturning Services Agreement, dated March 3, 2008

 Exhibit 10.14.1 
 [*] = CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS 
 DOCUMENT PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED 
 MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE 

COMMISSION. 
 FIRST AMENDMENT TO

 MANUFACTURING SERVICES AGREEMENT 
 This First Amendment to Manufacturing Services Agreement (this “Amendment”), is made as of this 3 day of March, 2008 (“Effective Date”), by and between Targanta Therapeutics
Corporation, a Delaware corporation, with a place of business at 225 South East Street, Suite 390, Indianapolis, IN 46202 (“Targanta”), and Catalent Pharma Solutions, LLC (f/k/a Cardinal Health PTS, LLC), a Delaware limited
liability company, with a place of business at 4401 Alexander Blvd. NE, Albuquerque, NM 87107 (“Catalent”). 
 RECITALS

 A. Targanta and Catalent have entered into that certain Manufacturing Services
Agreement dated the 27th of March 2007 (the “MSA”), pursuant to which Catalent has agreed to manufacture certain pharmaceutical
products for Targanta; 
 B. Targanta and Catalent desire to amend the MSA. 
 THEREFORE, in consideration of the mutual covenants, terms and conditions set forth below, the parties agree as follows: 
 1. Definitions. 
 A. Capitalized terms used and not
otherwise defined in this Amendment shall have the meanings assigned to them in the MSA. For clarity, the term “Agreement” as used in the MSA and herein shall mean the MSA as amended hereby. 
 B. Section 1.5 is amended by deleting it in its entirety and replacing it with the following: 
  

	 	“1.5.1	“Calendar Quarter” means a period of three (3) consecutive months commencing on January 1, April 1, July 1 or October 1 of any Calendar
Year. 

  

	 	1.5.2	“Calendar Year” means a period of twelve (12) consecutive months commencing on January 1 and ending on December 31.” 

 C. Section 1.25 is amended by deleting “Section 4.3” and replacing it with “Section 4.2”. 
 2. Catalent Divestiture and Name Change. 
 A. All
references to “Cardinal Health PTS, LLC” in the MSA shall be deemed references to “Catalent Pharma Solutions, LLC” and all references to “Cardinal Health” in the Evaluation Agreement shall be deemed references to
“Catalent”. 
 B. Article 17 of the MSA is hereby amended by deleting the Catalent “copy to” name and address in its
entirety and replacing it with the following: 
      Catalent Pharma Solutions, LLC 
      14 Schoolhouse Road 
      Somerset, New Jersey 08873 
      Attn: General Counsel (Legal Department)

      Facsimile: (732) 537-6491 

 C. Article 17 of the MSA is hereby amended by deleting the Targanta “copy to” name and address
in its entirety and replacing it with the following: 
      Targanta Therapeutics Corporation 
      222 Third Street, Suite 2300 
      Cambridge, Massachusetts 02142 
      Attn: General
Counsel 
      Facsimile: (617) 577-9021 
 3. Manufacturing Services. In connection with and/or as a result of the work to be pursued by the parties, the MSA is hereby amended, as follows. 
 A. Section 4.1 is amended by deleting it in its entirety and replacing it with the following: 
 “[*]. Beginning in [*] and during each [*] of the Term of this Agreement, the [*] shall be [*]. To fulfill
the [*], the required [*]; however, the parties hereby agree that Targanta may satisfy the [*] as follows: [*]. For clarity, Targanta’s total [*] for [*], even if [*]. If Targanta does not
purchase each [*] by its deadline (as described above), then within [*] after the relevant deadline, Targanta shall pay Catalent the difference between (i) the [*] had been fulfilled and (ii) the [*] up to the
deadline with respect to the [*] which is being fulfilled.” 
 B. Section 4.2 is hereby amended by adding the following
proviso to the end of the last sentence: 
 “; provided, that Catalent shall not be obligated to [*] in any [*].”

 C. It is noted that there is no Section 4.3 in the MSA. For ease of reference, the numbering is left as is. 
 4. No Other Variation. Except as expressly provided in this Amendment, all the terms, conditions and provisions of the MSA (including the rights, duties,
liabilities and obligations of the parties thereunder) remain in full force and effect, and shall apply to the construction of this Amendment. 
 5.
Governing Law. This Amendment shall be construed under and enforced in accordance with the laws of the state of Ohio, without regard to its conflicts of law principles. 
 6. Entire Agreement. This Amendment and the MSA, including their respective Attachments, constitute the entire agreement between the parties relating to the subject matter hereof and thereof, and may not be
varied except in writing signed by a duly authorized representative of each party. 
 7. Counterparts. This Amendment may be executed in one or more
counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. 
 [Signature page follows] 
  

	*	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 IN WITNESS WHEREOF, the parties have caused their respective duly authorized representatives to
execute this Agreement effective as of the Effective Date. 
  

									
	CATALENT PHARMA SOLUTIONS, LLC	 		 	TARGANTA THERAPEUTICS CORPORATION
					
	By:	 	/s/ Barry Littlejohns	 		 	By:	 	/s/ Roger Miller
	Name: Barry Littlejohns	 		 	Name: Roger Miller
	Its: VP & GM Injectables	 		 	Its: Site Head & VP of OperationsWaiver and Amendment Agreement

 Exhibit 10.24 
 WAIVER AND AMENDMENT AGREEMENT 
 This Waiver and Amendment Agreement (this
“Agreement”), dated as of February 22, 2008 (the “Amendment Agreement Date”), is entered into by and among HQ Sustainable Maritime Industries, Inc. (the “Company”), The
Tail Wind Fund Ltd. (“Tail Wind”) and Solomon Strategic Holdings, Inc. (“Solomon”, and together with Tail Wind, the “Investors”). 
 R E C I T A L S: 
 WHEREAS, the
Company and the Investors are parties to that certain Securities Purchase Agreement, dated as of November 3, 2006 (the “Purchase Agreement”), pursuant to which the Investors purchased $5 million in aggregate principal
amount of the Company’s 6.5% Convertible Notes due November 1, 2009 (the “Notes”) and pursuant to which the Company and the Investors entered into that certain Registration Rights Agreement dated as of
November 3, 2006 (the “Registration Rights Agreement”); capitalized terms used in this Agreement and not otherwise defined have the respective meanings ascribed thereto in the Purchase Agreement or Registration Rights
Agreement, as applicable; 
 WHEREAS, the Company has failed to timely cause a Registration Statement to be filed and declared effective
pursuant to the Registration Rights Agreement, and therefore the Company is current liable to the Investor for liquidated damages thereunder in accordance therewith; 
 WHEREAS, interest has been accruing under the Notes which has not yet been paid, part of which is past due; 
 WHEREAS, the Investors have agreed to waive all liquidated damages and interest accrued through March 31, 2008 in consideration for 300,000 shares of the Company’s Common Stock (“Waiver Shares”) in the
aggregate, upon the terms and subject to the conditions set forth herein; and 
 WHEREAS, the parties wish to include the Waiver Shares
issued hereunder as “Registrable Securities” under the Registration Rights Agreement; 
 A G R E E M E N T: 
 NOW, THEREFORE, in consideration of the foregoing and subject to the terms and conditions herein contained, the parties hereto agree as follows:

 Section 1 Waiver. 
 1.1 Waiver. Subject to the terms hereof and compliance by the Company with the terms of this Agreement, each of the Investors hereby waives (a) any and all liquidated damages accrued under the Registration Rights Agreement as a
result of the Company’s failure to timely file and cause to become effective a Registration Statement pursuant to the Registration Rights Agreement, (b) any and all future liquidated damages which would otherwise hereafter accrue 

  

 1 

 
under the Registration Rights Agreement as a result of the Company’s failure to timely file and cause to become effective a Registration Statement
pursuant to the Registration Rights Agreement, and (c) any and all interest accrued under the Notes from the issuance thereof through March 31, 2008. 
 1.2 Waiver Shares. Within seven (7) business days following the execution hereof by all the parties hereto, the Company shall (a) issue 255,000 Waiver Shares to Tail Wind and 45,000 Waiver Shares to
Solomon, which shares shall be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company, and (b) deliver stock certificates evidencing such Waiver Shares to the Investors.

 1.3 Purchase Agreement. The terms and conditions of the Purchase Agreement, as amended hereby, shall govern the Waiver Shares,
mutatis mutandis, with the Purchase Agreement being hereby amended such that (i) the term “Securities” shall also include the Waiver Shares, and (ii) the term “Agreements” shall also include this Agreement. To the
extent such terms are incorporated by reference in the Registration Rights Agreement, such terms shall have such amended meanings therein. 
 1.4 Disclosure. The Company shall, by 8:30 a.m. (New York City time) on the second Trading Day following the date on which this Agreement is executed by all parties hereto, issue a Current Report on Form 8-K disclosing the material
terms of the transactions contemplated hereby and attaching this Agreement as an exhibit thereto. The Company and the Investors shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby.

 Section 2 Registration Rights Agreement. The Registration Rights Agreement shall apply mutatis mutandis to the Waiver
Shares (including without limitation the indemnification and contribution provisions contained therein) and, without limiting the foregoing, a new or amended Registration Statement covering such Waiver Shares shall be promptly filed, and the Company
shall use its best efforts to cause such Registration Statement to be declared effective as soon as possible. After such Registration Statement is declared effective, the Company shall cause such Registration Statement and the prospectus contained
therein to remain effective and current with respect to the Waiver Shares for at least one year from the date of issuance of the Waiver Shares. 
 Section 3 Miscellaneous. 
 3.1 Except as waived and amended hereby and for the purposes described herein, the Purchase
Agreement, the Registration Rights Agreement and Notes shall remain in full force and effect in accordance with their respective terms. Except for the waiver and amendment contained herein, this Agreement shall not in any way waive or prejudice any
of the rights of the Investors or obligations of the Company under the Notes or other Agreements, or under any law, in equity or otherwise, and such waiver and amendment shall not constitute a waiver or amendment of any other provision of the Notes
or other Agreements nor a waiver or amendment of any subsequent default or breach of any obligation of the Company or of any subsequent right of the Investors. For clarification, the Warrants remain outstanding and in full force and effect and shall
not be affected hereby. 
  

 2 

 3.2 This Agreement shall be governed by and construed in accordance with the laws of the State of New
York applicable to contracts made and to be performed within such state. 
 3.3 This Agreement may be executed in any number of counterparts,
each of which will be deemed an original, but all of which together will constitute one and the same instrument. This Agreement may be executed by facsimile or by email of PDF image files. 
 3.4 Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other
agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby. 

[Signature Pages Following] 
  

 3 

 IN WITNESS WHEREOF, the undersigned have duly executed this Agreement as of the date first-above written.

  

					
	 THE COMPANY:
  
 HQ SUSTAINABLE MARITIME INDUSTRIES, INC.

		
	By:	 	/s/ NORBERT SPORNS
	 Name: Norbert Sporns
 Title:
CEO

	
	 THE PURCHASERS:
  
 THE TAIL WIND FUND LTD.

		
	By:	 	 TAIL WIND ADVISORY AND
 MANAGEMENT LTD., as

 investment manager

			
		 	By:	 	/s/ DAVID CROOK
		 	 Name: David Crook
 Title:
CEO

		
		 	SOLOMON STRATEGIC HOLDINGS, INC.
		
	By:	 	/s/ ANDREW P. MACKELLAR
	 Name: Andrew P. MacKellar
 Title: Director

  

 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}]]